Bone Sarcomas

(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA

(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA

(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA

(P 017) CLINICAL PROGRESSION ON NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EXTREMITY OSTEOSARCOMA

(P 018) COMPLETE RESPONSE TO MODEST DOSE RADIATION IN OSTEOSARCOMA METASTASIS IN TWO PATIENTS WITH LI-FRAUMENI SYNDROME

(P 019) COUMERMYCIN-A1 (CA1) IDENTIFIED AS A FIRST-IN-CLASS CDC45-MCM-GINS HELICASE INHIBITOR OFFERING THERAPEUTIC POTENTIAL FOR OSTEOSARCOMA TREATMENT

(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES

(P 022) EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS

(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP

(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION

(P 025) INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS

(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.

(P 027) LEPTOMENINGEAL ENHANCEMENT WITH NEUROLOGIC CHANGES IN PEDIATRIC BONE SARCOMA PATIENTS: A DIAGNOSTICAL CHALLENGE

(P 028) LONG TERM SURVIVAL OF AN ANTERIOR SKULL BASE OSTEOSARCOMA ARISING FROM FIBROUS DYSPLASIA TREATED WITH TRIMODALITY THERAPY

(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.

(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS

(P 031) PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE

(P 032) PLEURAL RELAPSE OF OSTEOSARCOMA AFTER TALC PLEURODESIS

(P 033) REDUCED H3K27ME3 IMMUNOEXPRESSION IN PEDIATRIC OSTEOSARCOMA IS ASSOCIATED WITH POOR RESPONSE TO NEOADJUVENT THERAPY

(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS

(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS

(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA

(P 037) SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA

(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA

(P 040) TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY

(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS

(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL

(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA